Is a treat-to-target approach to lipid-lowering therapy appropriate in patients with chronic kidney disease? A prospective French cohort study

[1]  M. Landray,et al.  The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial , 2011, The Lancet.

[2]  C. Jacquelinet,et al.  Prevalence of atheromatous and non-atheromatous cardiovascular disease by age in chronic kidney disease. , 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  Charles E McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[4]  A. Hoes,et al.  2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention , 2016, Atherosclerosis.

[5]  Notice , 1932, Journal of the Royal Asiatic Society.

[6]  Lawrence A Leiter,et al.  Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management , 2015, European heart journal.

[7]  C. Jacquelinet,et al.  Risk profile, quality of life and care of patients with moderate and advanced CKD: The French CKD-REIN Cohort Study , 2019, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  L. Juillard,et al.  Modified Lipids and Lipoproteins in Chronic Kidney Disease: A New Class of Uremic Toxins , 2016, Toxins.

[9]  W. März,et al.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005, The New England journal of medicine.

[10]  S. Grundy,et al.  2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.

[11]  C. Zoccali,et al.  Lipid management in patients with chronic kidney disease , 2018, Nature Reviews Nephrology.

[12]  David C. Wheeler,et al.  KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease Foreword , 2013 .

[13]  C. Jacquelinet,et al.  The French Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) cohort study , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[14]  M. Woodward,et al.  Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis , 2010, The Lancet.

[15]  Gert Mayer,et al.  Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. , 2009, The New England journal of medicine.

[16]  A. Hoes,et al.  2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. , 2016, European heart journal.

[17]  R. Garrick.  The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial , 2011 .

[18]  D. de Zeeuw,et al.  LDL cholesterol in CKD--to treat or not to treat? , 2013, Kidney international.

[19]  M. Taskinen,et al.  [ESC/EAS Guidelines for the management of dyslipidaemias]. , 2011, Revista espanola de cardiologia.

[20]  R. Hegele,et al.  Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. , 2011, The Canadian journal of cardiology.

[21]  G. Boysen,et al.  European Guidelines on Cardiovascular Disease Prevention , 2009, International journal of stroke : official journal of the International Stroke Society.

[22]  D. Santoro,et al.  Lipid disorders in patients with renal failure: Role in cardiovascular events and progression of chronic kidney disease , 2016, Journal of clinical & translational endocrinology.

[23]  P. Ridker,et al.  Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. , 2010, Journal of the American College of Cardiology.

[24]  Akshay S. Desai,et al.  2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. , 2018, Journal of the American College of Cardiology.

[25]  J. Ferrières,et al.  Achievement of Low-Density Lipoprotein Cholesterol Targets in CKD , 2019, Kidney international reports.

[26]  M. Woodward,et al.  Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis , 2010, The Lancet.

[27]  M. Pencina,et al.  Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy--a meta-analysis of 11 randomized controlled trials involving 21,295 participants. , 2013, Pharmacological research.

[28]  A. Keech,et al.  Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial. , 2019, Journal of the American College of Cardiology.

[29]  Deepak L. Bhatt,et al.  Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial , 2020, European heart journal.

[30]  A. Hoes,et al.  [Guidelines on cardiovascular disease prevention in clinical practice]. , 2005, Revue medicale de Liege.

[31]  M. Sabatine,et al.  2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. , 2019, European heart journal.

[32]  C. Jacquelinet,et al.  Adverse Drug Reactions in Patients with CKD. , 2020, Clinical journal of the American Society of Nephrology : CJASN.

[33]  Marcello Tonelli,et al.  Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study , 2012, The Lancet.

[34]  James E. Tcheng,et al.  2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials , 2018, Circulation.